MedTrace Logo

Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa

NCT06738771 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2026-04-30

No results posted yet for this study

Summary

The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam/beta-lactamase inhibitor combination, cefiderocol or older agents such as aminoglycosides and colistin) in unselected patients with infection due to difficult-to-treat P. aeruginosa.

Conditions

  • Pseudomonas Infections
  • Pseudomonas Aeruginosa
  • Prognosis
  • Drug Resistance, Multiple, Bacterial
  • Antibacterial Agents
  • Beta-lactam Antibiotics

Sponsors & Collaborators

  • Centre Hospitalier Régional d'Orléans

    lead OTHER

Principal Investigators

  • Francois BARBIER, Professor · Centre Hospitalier Universitaire d'Orléans

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-11
Primary Completion
2027-01-31
Completion
2027-01-31

Countries

  • France
  • Reunion

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06738771 on ClinicalTrials.gov